Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease
US12076334B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2022 |
| Grant date | Sep 3, 2024 |
| Priority date | — |
| Expiry date | Jul 18, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.